New Product in Development Looks to Help Patients with Clostridium Difficile

In the world of gastrointestinal conditions clostridium difficile, or c-diff is becoming a more common condition confronting doctors. Finding the best treatment method remains to be seen.

Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine discussed the development of one such potential treatment option being developed during the annual ID Week conference in San Diego.